4c075dfa-f213-4e97-9c4e-6aac7b8345c7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- OXIDATIVE_PHOSPHORYLATION+0.600
- ANGIOGENESIS+0.500
- COAGULATION+0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- ADIPOGENESIS+0.400
- COMPLEMENT+0.400
- FATTY_ACID_METABOLISM+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
Top 10 suppressed
- MITOTIC_SPINDLE-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- G2M_CHECKPOINT-0.300
- DNA_REPAIR-0.200
- E2F_TARGETS-0.200
- HEDGEHOG_SIGNALING-0.200
- INTERFERON_ALPHA_RESPONSE-0.100
- MYC_TARGETS_V2-0.100
- PI3K_AKT_MTOR_SIGNALING-0.100
- MYC_TARGETS_V1+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0AY-01A-21R-A00Z-07 | — | A | 0.900 |
| 2 | SRR15030843 | — | — | 0.875 |
| 3 | TCGA-39-5039-01A-01R-1443-07 | — | cohortSQ1 | 0.864 |
| 4 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.856 |
| 5 | SRR33532823 | — | C | 0.856 |
| 6 | SRR5088906 | — | — | 0.837 |
| 7 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.836 |
| 8 | 20040010.TNBC | — | F | 0.833 |
| 9 | 27871087-0449-4f04-bc72-a975681a198a | — | — | 0.833 |
| 10 | 88652d2f-b913-41e8-bd7c-c40967e94d5f | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |